Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

References

• Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother. 2013;9:162–71. doi:10.4161/hv.22302.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12–20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• ECDC. European centre for disease prevention and control. Surveillance of invasive bacterial diseases in Europe; 2012 [accessed 2017 Oct 20]. http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1261.
   Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63. doi:10.1016/j.vaccine.2009.04.063.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echaniz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Pollard AJ. Can we control all-cause meningococcal disease in Europe? Clin Microbiol Infect. 2016;22(Suppl 5):S103–S112. doi:10.1016/j.cmi.2016.03.006.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2016. Stockholm, Sweden: ECDC; 2018; p. 1–11.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016. [accessed 2018 May 07]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf
   Google Scholar
• Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107:3770–75. doi:10.1073/pnas.0915162107.
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789–99. doi:10.1084/jem.20021911.
   PubMed Web of Science ®Google Scholar
• Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, Rappuoli R, Pizza M, Aricò B. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55:687–98. doi:10.1111/j.1365-2958.2004.04423.x.
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. doi:10.1016/j.vaccine.2012.01.033.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968–74. doi:10.1016/j.vaccine.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416–25. doi:10.1016/S1473-3099(13)70006-9.
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, Carlone G, Medini D. Meningococcal Antigen Typing System (MATS)-based neisseria meningitidis serogroup b coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2:pii: e00261-00217. doi:10.1128/mSphere.00261-17.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77:234–52. doi:10.1128/MMBR.00056-12.
   PubMed Web of Science ®Google Scholar
• Pillai S, Howell A, Alexander K, Bentley BE, Jiang H-Q, Ambrose K, Zhu D, Zlotnick G. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine. 2005;23:2206–09. doi:10.1016/j.vaccine.2005.01.056.
   PubMed Web of Science ®Google Scholar
• Jiang H-Q, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086–93. doi:10.1016/j.vaccine.2010.06.083.
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093–107. doi:10.1016/j.vaccine.2006.03.091.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388:2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Carmona Martinez A, Simko R, Infante Marquez P, Arimany JL, Gimenez-Sanchez F, Couceiro Gianzo JA, Kovacs E, Rojo P, Wang H, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. J Infect. 2018;76:258–69. doi:10.1016/j.jinf.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017;35:395–402. doi:10.1016/j.vaccine.2016.11.009.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; group EUMBIVS. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–35. doi:10.1016/S0140-6736(12)61961-8.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM. Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine. 2015;33:3850–58. doi:10.1016/j.vaccine.2015.06.079.
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Wang H, Toneatto D, Dull PM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Cmaj. 2013;185:E715–724. doi:10.1503/cmaj.130257.
   PubMed Web of Science ®Google Scholar
• McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu L-M, Toneatto D, D’Agostino D, Dull PM, Pollard AJ. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. Cmaj. 2015;187:E215–223. doi:10.1503/cmaj.141200.
   PubMed Web of Science ®Google Scholar
• Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Kittel C, Toneatto D, Dull PM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis. 2013;32:1116–21. doi:10.1097/INF.0b013e31829cfff2.
   Google Scholar
• McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis. 2014;33:760–66. doi:10.1097/INF.0000000000000327.
   Google Scholar
• Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza M, Donnelly J. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023–30. doi:10.1016/j.vaccine.2010.05.014.
   PubMed Web of Science ®Google Scholar
• Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, et al. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 Months of age. Pediatr Infect Dis. 2016;35:e113–123. doi:10.1097/INF.0000000000001056.
   Google Scholar
• Sadarangani M, Sell T, Iro MA, Snape M, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, et al. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. Cmaj. 2017;189:E1276–E1285. doi:10.1503/cmaj.161288.
   PubMed Web of Science ®Google Scholar
• Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33:5217–24. doi:10.1016/j.vaccine.2015.06.103.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, Toneatto D, Graña G, Wang H, Dull PM. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9:2304–10. doi:10.4161/hv.25505.
   PubMed Web of Science ®Google Scholar
• Watson PS, Novy P, Bekkat-Berkani R, Strubbe F, Banzhoff A. Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data. Expert Rev Vaccines. 2019:1–10. doi:10.1080/14760584.2019.1580579.
   PubMed Web of Science ®Google Scholar
• Nolan T, Santolaya ME, de Looze F, Marshall H, Richmond P, Henein S, Rheault P, Heaton K, Perrett KP, Garfield H, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37:1209–18. doi:10.1016/j.vaccine.2018.12.059.
   PubMed Web of Science ®Google Scholar
• Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, Kleinschmidt A, McCarthy M, Wang H, Toneatto D, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35:427–34. doi:10.1016/j.vaccine.2016.11.071.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Block SL, Jackowska T, Konior R, D’Agostino D, Smolenov I, Toneatto D, Welsch JA. Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study. Pediatr Infect Dis J. 2018;37:475–82. doi:10.1097/INF.0000000000001896.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bexsero, meningococcal group-B vaccine (rDNA, component, adsorbed). Product Information. 2018. [accessed 2018 September 13]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Nolan T, Garfield H, Gupta A, Ferguson M, Marshall H, D’Agostino D, Toneatto D. Persistence of bactericidal activity at 4 years after 2 primary doses of a recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) and response to a booster dose in adolescents and young adults. IDWeek. Open Forum Infect Dis. 2017;4(Suppl 1):S322. doi:10.1093/ofid/ofx163.757.
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine. 2005;23:2222–27. doi:10.1016/j.vaccine.2005.01.051.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Pizza M, Masignani V, Rappuoli R. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines. 2017;16:433–51. doi:10.1080/14760584.2017.1308828.
   PubMed Web of Science ®Google Scholar
• Lagos RE, Munoz AE, Levine MM, Lepetic A, Francois N, Yarzabal JP, Schuerman L. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin. 2011;7:511–22. doi:10.4161/hv.7.5.14634.
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine. 1998;16:921–27.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Bartolini E, Galli B, Santini L, Lo Surdo P, Buricchi F, Bruttini M, Benucci B, Pacchiani N, Alleri L, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018;8:3700. doi:10.1038/s41598-018-22057-7.
   PubMed Web of Science ®Google Scholar
• Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine. 2011;29:1968–73. doi:10.1016/j.vaccine.2010.12.075.
   PubMed Web of Science ®Google Scholar
• Ladhani S Safety and efficacy of MenB vaccination in the UK. MRF Conference, 14-15 November, 2017, London. [accessed 2018 June 26]. https://www.meningitis.org/mrf-conference-2017.
   Google Scholar
• Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016. Emerg Infect Dis. 2017;23:1184–87. doi:10.3201/eid2307.170236.
   PubMed Web of Science ®Google Scholar
• Law DK, Lorange M, Ringuette L, Dion R, Giguere M, Henderson AM, Stoltz J, Zollinger WD, De Wals P, Tsang RS. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol. 2006;44:2743–49. doi:10.1128/JCM.00601-06.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64:1263–67. doi:10.1093/cid/cix154.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, MacNeil JR, Patel M, Bhavsar T, Cohn AC, Dinitz-Sklar J, Duffy J, Finnie J, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804. doi:10.1542/peds.2014-4015.
   PubMed Web of Science ®Google Scholar
• Patel M, Briere E, Duffy J, Miller M, Breakwell L, McNamara L, Kratz N, Izzo R, Yu Y, Bhavsar T, et al. Use of a novel serogroup B meningococcal vaccine in response to two university outbreaks in the US (Abstract O22). IPNC, 2014. [accessed 2017 October 2]. http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf.
   Google Scholar
• Biswas HH, Han GS, Wendorf K, Winter K, Zipprich J, Perti T, Martinez L, Arellano A, Kyle JL, Zhang P, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university – California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:520–21. doi:10.15585/mmwr.mm6520a3.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123–31. doi:10.1016/S0140-6736(14)60842-4.
   PubMed Web of Science ®Google Scholar
• Vetter V, Baxter R, Denizer G, Map S, Silfverdal S-A, Vyse A, Borrow R. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15:641–58. doi:10.1586/14760584.2016.1130628.
   PubMed Web of Science ®Google Scholar